Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805151 | 0.80 | KMT2A (0.42) | MALT1IDO1KMT2ATDP1 | |
| SCHEMBL3637629 | 0.80 | MALT1 (0.47) | MALT1IDO1KMT2AKCNA5DRD2 | |
| SCHEMBL5557644 | 0.80 | KMT2A (0.60) | MALT1IDO1KMT2ABCHE | |
| SCHEMBL732427 | 0.78 | KMT2A (0.68) | MALT1IDO1KMT2ATDP1TPSAB1 | |
| SCHEMBL13631378 | 0.78 | KMT2A (0.65) | MALT1IDO1KMT2ATDP1TPSAB1 | |
| SCHEMBL29625033 | 0.78 | KMT2A (0.65) | MALT1IDO1KMT2ATDP1TPSAB1 | |
| SCHEMBL22552972 | 0.77 | KMT2A (0.41) | MALT1IDO1KMT2ATDP1TPSAB1 | |
| SCHEMBL15684645 | 0.77 | KMT2A (0.52) | MALT1IDO1KMT2ATDP1 | |
| SCHEMBL31307358 | 0.77 | KMT2A (0.51) | MALT1KMT2ADRD2TDP1TPSAB1 | |
| SCHEMBL13247459 | 0.77 | KMT2A (0.57) | MALT1IDO1KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428524-B2 | Synthetic process for the manufacture of ecteinascidin compounds | PHARMA MAR, S.A. (ES) | 2016-08-30 | — | — | US | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | SERPINH1, ERLIN2, PTMA | MALT1 4279/4885IDO1 2891/4885KMT2A 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.